about
Nosocomial bloodstream infections caused by Klebsiella pneumoniae: impact of extended-spectrum beta-lactamase (ESBL) production on clinical outcome in a hospital with high ESBL prevalenceAntimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolatesEfflux pumps expression and its association with porin down-regulation and beta-lactamase production among Pseudomonas aeruginosa causing bloodstream infections in BrazilBloodstream infections with metallo-beta-lactamase-producing Pseudomonas aeruginosa: epidemiology, microbiology, and clinical outcomes.Pyrosequencing-based analysis reveals a novel capsular gene cluster in a KPC-producing Klebsiella pneumoniae clinical isolate identified in BrazilA hospital-based matched case-control study to identify clinical outcome and risk factors associated with carbapenem-resistant Klebsiella pneumoniae infectionCation concentration variability of four distinct Mueller-Hinton agar brands influences polymyxin B susceptibility results.Detection of SPM-1-producing Pseudomonas aeruginosa and class D β-lactamase-producing Acinetobacter baumannii isolates by use of liquid chromatography-mass spectrometry and matrix-assisted laser desorption ionization-time of flight mass spectrometryKlebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae in the intensive care unit: a real challenge to physicians, scientific community, and society.Old antibiotics for multidrug-resistant pathogens: from in vitro activity to clinical outcomes.Outbreak of OXY-2-Producing Klebsiella oxytoca in a renal transplant unit.Temporal evolution of polymyxin B-resistant klebsiella pneumoniae clones recovered from blood cultures in a teaching hospital during a 7-year period.The route of antimicrobial resistance from the hospital effluent to the environment: focus on the occurrence of KPC-producing Aeromonas spp. and Enterobacteriaceae in sewage.First isolation of metallo-beta-lactamase-producing multiresistant Klebsiella pneumoniae from a patient in Brazil.Comparison of phenotypic tests for detecting BKC-1-producing Enterobacteriaceae isolates.Influence of disk preparation on detection of metallo-beta-lactamase-producing isolates by the combined disk assay.beta-Lactam MICs correlate poorly with mutant prevention concentrations for clinical isolates of Acinetobacter spp. and Pseudomonas aeruginosaLinezolid resistance in Brazilian Staphylococcus hominis strains is associated with L3 and 23S rRNA ribosomal mutationsFirst report of plasmid-mediated resistance to quinolones and cefotaxime in an Enterobacter cloacae strain isolated from an outpatient in Brazil.Further identification of CTX-M-2 extended-spectrum beta-lactamase in Pseudomonas aeruginosa.Temporal evolution of carbapenem-resistant Acinetobacter baumannii in Curitiba, southern Brazil.First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil.Cloverleaf test (modified Hodge test) for detecting carbapenemase production in Klebsiella pneumoniae: be aware of false positive results.Emergence of the extended-spectrum beta-lactamase GES-1 in a Pseudomonas aeruginosa strain from Brazil: report from the SENTRY antimicrobial surveillance program.Prevalence and clinical outcomes of episodes of ventilator-associated pneumonia caused by SPM-1-producing and non-producing imipenem-resistant Pseudomonas aeruginosa.Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (199Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999.Occurrence of single-point gyrA mutations among ciprofloxacin-susceptible Escherichia coli isolates causing urinary tract infections in Latin America.In vitro susceptibility of Stenotrophomonas maltophilia isolates: comparison of disc diffusion, Etest and agar dilution methods.Prevalence of extended spectrum beta-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998-99).Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan. Japan Antimicrobial Resistance Study Group.Urinary tract infection trends in Latin American hospitals: report from the SENTRY antimicrobial surveillance program (1997-2000).Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia in Latin America: frequency of occurrence and antimicrobial susceptibility profile: results from the SENTRY Antimicrobial Surveillance Program (1997-2000).Salmonella spp. isolates causing bloodstream infections in Latin America: report of antimicrobial activity from the SENTRY Antimicrobial Surveillance Program (1997-2000).An outbreak of catalase-negative methicillin-resistant Staphylococcus aureus.Antimicrobial susceptibility of Streptococcus pneumoniae in Latin America: results from five years of the SENTRY Antimicrobial Surveillance Program.Resistance trends of Acinetobacter spp. in Latin America and characterization of international dissemination of multi-drug resistant strains: five-year report of the SENTRY Antimicrobial Surveillance Program.IMPs, VIMs and SPMs: the diversity of metallo-beta-lactamases produced by carbapenem-resistant Pseudomonas aeruginosa in a Brazilian hospital.Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres.Beta-lactam resistance mechanisms in Pseudomonas aeruginosa strains causing bloodstream infections: comparative results between Brazilian and American isolates.
P50
Q25257162-DA558F8B-4746-4BFA-BBB7-D344D36F0E88Q28374993-F60CEC03-B99B-4404-BAEE-E706C6C49CCFQ33655586-CF5E6067-5D2B-4BAA-9773-CDB14E655657Q34301486-FCD59E35-79BE-4246-9A8C-28110C9052A7Q34375571-CC2FF0CD-DA40-4FED-852C-C2A3F7BF8F6EQ34582295-288230A4-75E0-4625-9740-A675985DC361Q36118781-1490BCB8-5B51-4C4A-A424-D1D892FBD918Q36506376-6BCAC7B3-8683-4464-B1F7-E79BC53F9E2CQ38088534-9A674576-FC71-4B41-B412-C51EEF3F4C3BQ38994727-B449257C-2B16-4961-BA29-38F82180D7C1Q39761048-6C3BE29E-7E23-4B28-9993-9B6AD0953E67Q40050133-B19AAB05-56F5-4A1E-8AC8-6A128F716404Q40097095-0B85989E-C864-41F1-91EB-F13778B1B6F4Q40770302-361323D2-BEFB-4D6E-A190-86D98CE8A4E7Q40840661-F6CBB00A-8575-4D58-BEDC-AC703F9172FFQ41945397-D8D02A7E-E2CE-47A8-80E2-4459F6DC0F19Q42408812-78D8F073-640A-4DC9-9EE5-4CBF5F20DE52Q42703527-D1A1764F-54E9-453A-B127-751E25B61817Q42956936-79C05C69-8925-4D3B-BD26-5BC5F5D5B111Q43128332-44DE3385-41A1-4D11-8091-CA42659C6B03Q43177926-5DA987E5-A074-4429-A72B-D2210371AED6Q43215495-EE0AB84B-F150-4658-B225-B0CC8565EF62Q43227341-2CA00F6D-872D-4619-BFD5-9B13624C0D92Q43240164-F9728F94-1B5A-40D2-A01E-A4269F68244FQ43558011-5AB57F41-FD8D-422A-A365-480FDD4EDE43Q43587149-9959EAE5-DCB5-4EA3-A358-999BD8DCF4CFQ43587157-18AE7B25-DDF3-4A54-954B-52527A9EA09FQ43839177-ACA0F731-5D95-4603-B00C-352A0090DBFBQ43875969-AA6DB2A7-9A40-442C-A81F-9EF9CFB8D4A1Q43945108-446859CE-368F-4445-B6EF-5AF48025C134Q44232178-9512F404-7D31-48E5-AA1F-70D581347958Q44256805-3A3CF600-A184-494D-9777-2ACB530002FDQ44256808-7A7804CA-9426-479E-A1E1-9E23AF445626Q44256811-4D30F2F1-8094-419F-8CFE-05E22B5F0036Q44414384-79536ED7-7FB9-4FF2-9B72-3394680D34E5Q44950211-A37979A1-EC66-40AE-8B33-B440E09B84FFQ45027537-AAC4BB4F-9F46-4C6C-ADE4-5089FF3D5EC3Q45222975-46282D01-285D-4048-AE34-2A931F5E7A7DQ45243569-76CF312B-AD13-4C5A-AD1D-B83B2186266BQ46943275-62AB8F92-0A1D-4109-9446-37E9F40A2E9F
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Ana C. Gales
@ast
Ana C. Gales
@en
Ana C. Gales
@es
Ana C. Gales
@nl
type
label
Ana C. Gales
@ast
Ana C. Gales
@en
Ana C. Gales
@es
Ana C. Gales
@nl
prefLabel
Ana C. Gales
@ast
Ana C. Gales
@en
Ana C. Gales
@es
Ana C. Gales
@nl
P1053
C-8280-2013
P106
P1153
7003717341
P21
P31
P3829
P496
0000-0003-0913-768X